Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

Ceftazidime-Avibactam in Different Patient Populations

APR 26, 2017 | CONTAGION® EDITORIAL STAFF


Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, explains how her future research aims to understand the effects of ceftazidime-avibactam in different patient populations.
 
Interview Transcript (slightly modified for readability)
 
“I’m actually continuing to collect data from the hospital I was at, as well as the other 8 hospitals that were involved in this study to try and get as many patients into the study as possible. Again, it’s retrospective, so we’re going back a few months and saying, ‘okay, what patients received this in the past few months?’ [and analyzing that]. We’re not doing any prospective collection at this point.
 
What I will be trying to evaluate as I delve further into the research that I did [the effects of treatments on] patients who received ceftazidime-avibactam by itself versus with other agents. [I will evaluate] if that made a difference in mortality or clinical success or microbiologic success, (because I think that will be important going forward). [We’ll also] just [be] seeing what patients that it worked with, kind of trying to tease out [how treatment effected] patients who were in the ICU [Intensive Care Unit] or not in the ICU, patient who were immunocompromised versus not. What patients it worked well in, and if we can come up with any recommendations based on that.”
 
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


FEATURED
We break down our top HIV news stories of 2017. Did you read them all?
x